Format

Send to

Choose Destination
Surv Ophthalmol. 2018 May - Jun;63(3):340-346. doi: 10.1016/j.survophthal.2017.07.005. Epub 2017 Aug 4.

Treatment of ocular rosacea.

Author information

1
Department of Ophthalmology, Ophthalmic Plastic Surgery, Lions Eye Institute, Albany Medical College, Slingerlands, New York, USA; Division of Otolaryngology, Department of Surgery, Albany Medical College, Slingerlands, New York, USA. Electronic address: tedwladis@gmail.com.
2
Department of Molecular and Cellular Physiology, Albany Medical College, Slingerlands, New York, USA; Department of Ophthalmology, Lions Eye Institute, Albany Medical College, Slingerlands, New York, USA.

Abstract

Although rosacea is a common entity with significant cosmetic, socioeconomic, and vision-threatening impacts, this disorder remains incurable. Furthermore, until quite recently many of the therapeutic options for rosacea had not been assessed through rigorous clinical testing with meaningful outcome measures. Nonetheless, new medical and surgical interventions that have been validated in well-designed trials hold the promise of treating rosacea more effectively. Furthermore, recent enhancements in our understanding of the cellular and molecular biology offer highly translational insights that will hopefully lead to the development of new treatment options for rosacea. We review the evidence for these therapies and discuss new scientific findings that can be exploited for new therapeutic interventions.

KEYWORDS:

dry eye; eyelid; meibomian gland disease; ocular surface disease; rosacea

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center